Anti-cancer activity of nitrones in the ApcMin/ model of colorectal cancer

Free Radical Research

Volumn 44, Issue 1, 2010, Pages 108-117

  Floyd, Robert A ^a,b   Towner, Rheal A ^a,b   Wu, Dee ^b,c   Abbott, Andrew ^a   Cranford, Rebecca ^a   Branch, Dan ^a   Guo, Wei Xing ^a   Foster, Steven B ^c   Jones, Inna ^a   Alam, Rajib ^b   Moore, Danny ^d   Allen, Toby ^d   Huycke, Mark ^b,d  

^a OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF OKLAHOMA   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

ApcMin ; Colorectal cancer; HCT 116 cells; Nitrones; Oxaliplatin

Indexed keywords

4 HYDROXYPHENYL TERT BUTYL NITRONE; ANTINEOPLASTIC AGENT; CASPASE 3; DRINKING WATER; GADOLINIUM PENTETATE; N TERT BUTYL ALPHA PHENYLNITRONE; OXALIPLATIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL STRAIN HCT116; COLON CANCER; COLORECTAL CANCER; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG EFFICACY; DRUG SOLUBILITY; GLIOBLASTOMA; HUMAN; HUMAN CELL; IMAGE ANALYSIS; INTESTINE TUMOR; LIVER CANCER; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; SURVIVAL; TUMOR VOLUME;

ADENOMA; ANIMALS; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; GENES, APC; HCT116 CELLS; HUMANS; LOSS OF HETEROZYGOSITY; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NITROGEN OXIDES; SURVIVAL ANALYSIS;

MUS;

EID: 71649085248     PISSN: 10715762     EISSN: 10292470     Source Type: Journal    
DOI: 10.3109/10715760903321796     Document Type: Article

References (47)

1. Horner MJ, Ries LAG, Krapcho M, Neyman N, Aminou R, Howlader N, Altedruse N, Feuer SF, Huang L, Mariotto A, Miller BA, Lewis DR, Eisner MP, Stinchomb DG, Edwards BK. SEER cancer statistics review. 1006. National Cancer Institute; 1975.
2. Engstrom PF. Systemic therapy for advanced or metastatic colorectal cancer: National Comprehensive Cancer Network guidelines for combining anti-vascular endothelial growth factor and anti-epidermal growth factor receptor monoclonal antibodies with chemotherapy. Pharmacotherapy 2008;28: 18S-22S.
3. Floyd RA, Kotake Y, Hensley K, Nakae D, Konishi Y. Reactive oxygen species in choline defi ciency induced carcinogenesis and nitrone inhibition. Mol Cell Biochem 2002;234/235:195-203.
4. Nakae D, Kishida H, Enami T, Konishi Y, Hensley KL, Floyd RA, Kotake Y. Effects of phenyl N-tert-butyl nitrone and its derivatives on the early phase of hepatocarcinogenesis in rats fed a choline-defi cient, l-amino acid-defi ned diet. Cancer Sci 2003;94:26-31.
5. Nakae D, Kotake Y, Kishida H, Hensley KL, Denda A, Koba-yashi Y, Kitayama W, Tsujiuchi T, Sang H, Stewart CA, Tabatabaie T, Floyd RA, Konishi Y. Inhibition by phenyl N-tert-butyl nitrone on early phase carcinogenesis in the livers of rats fed a choline-defi cient, L-amino acid-defi ned diet. Cancer Res 1998;58:4548-4551.
6. Nakae D, Uematsu F, Kishida H, Kusuoka O, Katsuda S, Yoshida M, Takahashi M, Maekawa A, Denda A, KonishiY, Kotake Y, Floyd RA. Inhibition of the development of hepa-tocellular carcinomas by phenyl N-tert-butyl nitrone in rats fed with a choline-defi cient, L-amino acid-defi ned diet. Cancer Lett 2004;206:1-13.
7. Doblas S, Saunders D, Tesiram Y, Kshirsager P, Pye Q, Oblander J, Gordon B, Kosanke S, Floyd RA, Towner RA. Phenyl-tert-butyl-nitrone induces tumor regression and decreases angiogenesis in a C6 rat glioma model. Free Radic Biol Med 2007;44:63-72.
8. Janzen EG. Spin trapping. Acc Chem Res 1971;4:31-40.
9. Buettner GR. Spin trapping: ESR parameters of spin adducts. Free Radic Biol Med 1987;3:259-303.
10. Janzen EG. A critical review of spin trapping in biological systems., In: unknown editor. Free radicals in biology. Academic Press, Inc.; 1980. p. 115-154.
11. Mason RP, Chignell CF. Free radicals in pharmacology and toxicology-selected topics. Pharmacol Rev 1982;33: 189-211.
12. Poyer JL, Floyd RA, McCay PB, Janzen EG, Davis ER. Spin trapping of the trichloromethyl radical produced during enzymic NADPH oxidation in the presence of carbon tetra-chloride or carbon bromotrichloromethane. Biochim Biophys Acta 1978;539:402-409.
13. Bolli R, McCay PB. Use of spin traps in intact animals undergoing myocardial ischemia/reperfusion: a new approach to assessing the role of oxygen radicals in myocardial 'stunning'. Free Radic Biol Med 1990;9:3-6.
14. Bolli R, Patel BS, Jeroudi MO, Lai EK, McCay PB. Demonstration of free radical generation on 'stunned' myocardium of intact dogs with the use of the spin trap a-phenyl N-tert-butyl nitrone. J Clin Invest 1988;82:476-485.
15. Lai EK, Crossley C, Sridhar R, Misra HP, Janzen EG, McCay PB. In vivo spin trapping of free radicals generated in brain, spleen, and liver during gamma radiation of mice. Arch Bio-chem Biophys 1986;244:156-160.
16. Mason RP. Assay of in situ radicals by electron spin resonance. Methods Enzymol 1983;105:416-421.
17. Floyd RA. Protective action of nitrone-based free radical traps against oxidative damage to the central nervous system. Adv Pharmacol 1997;38:361-378.
18. Floyd RA. Nitrones as therapeutics in age-related diseases. Aging Cell 2006;5:51-57.
19. Maples KR, Green AR, Floyd RA. Nitrone-related therapeutics: potential of NXY-059 for the treatment of acute ischae-mic stroke. CNS Drugs 2004;18:1071-1084.
20. Floyd RA. Role of oxygen free radicals in carcinogenesis and brain ischemia. FASEB J 1990;4:2587-2597.
21. Moser AR, Luongo C, Gould KA, McNeley MK, Shoemaker AR, Dove WF. ApcMin: a mouse model for intestinal and mammary tumorigenesis. Eur J Cancer 1995;31A:1061-1064.
22. Aoki K, Taketo MM. Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene. J Cell Sci 2007;120: 3327-3335.
23. Haigis KM, Hoff PD, White A, Shoemaker AR, Halberg RB, Dove WF. Tumor regionality in the mouse intestine refl ects the mechanism of loss of Apc function. Proc Natl Acad Sci USA 2004;101:9769-9773.
24. Levy DB, Smith KJ, Beazer-Barclay Y, Hamilton SR, Vogel-stein B, Kinzler K W. Inactivation of both APC alleles in human and mouse tumors. Cancer Res 1994;54:5953-5958.
25. Moser AR, Dove WF, Roth KA, Gordon JI. The Min (multiple intestinal neoplasia) mutation: its effect on gut epithelial cell differentiation and interaction with a modifi er system. J Cell Biol 1992;116:1517-1526.
26. Shoemaker AR, Moser AR, Dove WF. N-ethyl-N-nitrosourea treatment of multiple intestinal neoplasia (Min) mice: age-related effects on the formation of intestinal adenomas, cystic crypts, and epidermoid cysts. Cancer Res 1995;55:4479-4485.
27. Oshima M, Oshima H, Kitagawa K, Kobayashi M, Itakura C, Taketo M. Loss of Apc heterozygosity and abnormal tissue building in nascent intestinal polyps in mice carrying a truncated Apc gene. Proc Natl Acad Sci USA 1995;92:4482-4486.
28. Jacoby RF, Marshall DJ, Newton MA, Novakovic K, Tutsch K, Cole CE, Lubet RA, Kelloff GJ, Verma A, Moser AR, Dove WF. Chemoprevention of spontaneous intestinal adenomas in the Apc Min mouse model by the nonsteroidal anti-infl am-matory drug piroxicam. Cancer Res 1996;56:710-714.
29. Jacoby RF, Seibert K, Cole CE, Kelloff G, Lubet RA. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenoma-tous polyposis. Cancer Res 2000;60:5040-5044.
30. Rao CV, Cooma I, Rodriguez JG, Simi B, El Bayoumy K, Reddy BS. Chemoprevention of familial adenomatous poly-posis development in the APC(min) mouse model by 1,4-phe-nylene bis(methylene)selenocyanate. Carcinogenesis 2000;21: 617-621.
31. Towner RA, Foley LM, Painter DM. Hepatocarcinogenesis tumor grading correlated with in vivo image-guided 1H-NMR spectroscopy in rat model. Toxicol Appl Pharmacol 2005; 207:237-244.
32. Towner RA, Hashimoto H, Summers PM. Non-invasive in vivo magnetic resonance imaging assessment of acute afl a-toxin B1 hepatotoxicity in rats. Biochim Biophys Acta 2000;1475:314-320.
33. Huie R, Cherry WR. Facile one-step synthesis of phenyl-tert-butylnitrone (PBN) and its derivatives. J Org Chem 1985;50:1531-1532.
34. Janzen EG, West MS, Kotake Y, DuBose CM. Biological spin trapping methodology. III. octanol-water partition coeffi cients of spin-trapping compounds. J Biochem Biophys Methods 1996;32:183-190.
35. Floyd RA,Kotake Y, Towner RA, Guo W-X, Nakae D, Konishi Y. Nitric oxide and cancer development. J Toxicol Pathol 2007;20:77-92.
36. Lala PK, Chakraborty C. Role of nitric oxide in carcinogenesis and tumour progression. Lancet Oncol 2001;2:149-156.
37. Lirk P, Hoffmann G, Rieder J. Inducible nitric oxide syn-thase-time for reappraisal. Curr Drug Targets Infl amm Allergy 2002;1:89-108.
38. Yagihashi N, Kasajima H, Sugai S, Matsumoto K, Ebina Y, Morita T, Murakami T, Yagihashi S. Increased in situ expression of nitric oxide synthase in human colorectal cancer. Virchows Arch 2000;436:109-114.
39. Kotake Y, Kishida H, Nakae D, Floyd RA. Nitric oxide production by primary liver cells isolated from amino acid diet fed rats. Methods Enzymol 2005;396:535-541.
40. Radisavljevic Z. Nitric oxide suppression triggers apoptosis through the FKHRL1 (FOXO3A)/ROCK kinase pathway in human breast carcinoma cells. Cancer 2003;97: 1358-1363.
41. Salvucci O, Carsana M, Bersani I, Tragni G, Anichini A. Antiapoptotic role of endogenous nitric oxide in human melanoma cells. Cancer Res 2001;61:318-326.
42. Torok NJ, Higuchi H, Bronk S, Gores GJ. Nitric oxide inhibits apoptosis downstream of cytochrome c release by nitrosylat-ing caspase 9. Cancer Res 2002;62:1648-1653.
43. Rao CV, Indranie C, Simi B, Manning PT, Connor JR, Reddy BS. Chemopreventive properties of a selective induc-ible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor. Cancer Res 2002;62: 165-170.
44. Ahn B, Ohshima H. Suppression of intestinal polyposis in ApcMin/+ mice by inhibiting nitric oxide production. Cancer Res 2001;61:8357-8360.
45. Kotake Y, Sang H, Miyajima T, Wallis GL. Inhibition of NF-kB, iNOS mRNA, COX2 mRNA, and COX catalytic activity by phenyl-N-tert-butylnitrone (PBN). Biochim Bio-phys Acta 1998;1448:77-84.
46. Tabatabaie T, Vasquez AM, Moore DR, Floyd RA, Kotake Y. Direct administration of interleukin-1 and interferon-g to rat pancreas leads to the in vivo production of nitric oxide and expression of inducible nitric oxide synthase and inducible cyclooxygenase. Pancreas 2001;23:316-322.
47. Kim SF, Huri DA, Snyder SH. Inducible nitric oxide synthase binds, S-nitrosylates, and activates cyclooxygenase-2. Science 2005;310:1966-1970.